Clinical Trial Update: Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer

View source ↗

Summary

A completed clinical trial evaluated EGFR and KRAS mutation status in patients with stage III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Lung Cancer | Status: COMPLETED